Home Breast Cancer Lunit preps for FDA approval, series D funding after getting EC nod...

Lunit preps for FDA approval, series D funding after getting EC nod | 2020-06-08

60
0

Hong Kong – South Korea’s Lunit Inc. is currently in the process of applying for U.S. FDA approval for Lunit Insight Mmg, its AI software that analyzes mammography images to detect breast cancer. Other markets that the company targets entering include South America, the Middle East, and Asia Pacific, Jussarang Lee, communications manager at Lunit, told BioWorld. Founded in 2013, the Seoul-based company uses artificial intelligence to develop cancer diagnostics and therapeutics.

Artificial intelligence Asia-Pacific BioWorld MedTech Cancer Software Series D Financings Digital health FDA

Already a subscriber? Sign in 

https://www.bioworld.com/articles/435648-lunit-preps-for-fda-approval-series-d-funding-after-getting-ec-nod

This site uses Akismet to reduce spam. Learn how your comment data is processed.